U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hereditary von Willebrand disease

MedGen UID:
1814986
Concept ID:
C5703318
Disease or Syndrome
Synonyms: congenital von willebrand disease; congenital von willebrand's disease; hereditary von Willebrand disease; hereditary von Willebrand disease (hereditary or acquired); vascular pseudohemophilia; Von Willebrand disease; von Willebrand's disease; von Willebrand-Jrgens disease
SNOMED CT: Hereditary von Willebrand disease (1259242002)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
Autosomal dominant inheritance
MedGen UID:
141047
Concept ID:
C0443147
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele.
 
Gene (location): VWF (12p13.31)
Related gene: GP1BA
 
Monarch Initiative: MONDO:0019565
Orphanet: ORPHA903

Disease characteristics

Excerpted from the GeneReview: von Willebrand Disease
Von Willebrand disease (VWD), a congenital bleeding disorder caused by deficient or defective plasma von Willebrand factor (VWF), may only become apparent on hemostatic challenge, and bleeding history may become more apparent with increasing age. Recent guidelines on VWD have recommended taking a VWF level of 30 or 40 IU/dL as a cutoff for those diagnosed with the disorder. Individuals with VWF levels greater than 30 IU/dL and lower than 50 IU/dL can be described as having a risk factor for bleeding. This change in guidelines significantly alters the proportion of individuals with each disease type. Type 1 VWD (~30% of VWD) typically manifests as mild mucocutaneous bleeding. Type 2 VWD accounts for approximately 60% of VWD. Type 2 subtypes include: Type 2A, which usually manifests as mild-to-moderate mucocutaneous bleeding; Type 2B, which typically manifests as mild-to-moderate mucocutaneous bleeding that can include thrombocytopenia that worsens in certain circumstances; Type 2M, which typically manifests as mild-moderate mucocutaneous bleeding; Type 2N, which can manifest as excessive bleeding with surgery and mimics mild hemophilia A. Type 3 VWD (<10% of VWD) manifests with severe mucocutaneous and musculoskeletal bleeding. [from GeneReviews]
Authors:
Anne Goodeve  |  Paula James   view full author information

Professional guidelines

PubMed

Kubo M, Matsumoto M
Int J Hematol 2023 Mar;117(3):331-340. Epub 2023 Feb 9 doi: 10.1007/s12185-023-03552-8. PMID: 36757521
Lavin M, O'Donnell JS
Hematology Am Soc Hematol Educ Program 2016 Dec 2;2016(1):683-689. doi: 10.1182/asheducation-2016.1.683. PMID: 27913547Free PMC Article
Neutze D, Roque J
Am Fam Physician 2016 Feb 15;93(4):279-86. PMID: 26926815

Recent clinical studies

Diagnosis

Sucker C, Senft B, Scharf RE, Zotz RB
Clin Appl Thromb Hemost 2006 Jul;12(3):305-10. doi: 10.1177/1076029606291428. PMID: 16959683
Gupta PK, Kannan M, Chatterjee T, Dixit A, Mahapatra M, Choudhry VP, Saxena R
Haemophilia 2006 Jul;12(4):452-5. doi: 10.1111/j.1365-2516.2006.01301.x. PMID: 16834752
Elli M, Pinarli FG, Dagdemir A, Dabak N, Fisgin T, Selcuk MB, Sultansuyu S, Acar S
Pediatr Hematol Oncol 2006 Mar;23(2):111-4. doi: 10.1080/08880010500457749. PMID: 16651239
Nitu-Whalley IC, Lee CA
Haemophilia 1999 Sep;5(5):318-26. doi: 10.1046/j.1365-2516.1999.00340.x. PMID: 10583513

Therapy

Elli M, Pinarli FG, Dagdemir A, Dabak N, Fisgin T, Selcuk MB, Sultansuyu S, Acar S
Pediatr Hematol Oncol 2006 Mar;23(2):111-4. doi: 10.1080/08880010500457749. PMID: 16651239
Schwarz HP, Dorner F, Mitterer A, Mundt W, Schlokat U, Pichler L, Turecek PL
Wien Klin Wochenschr 1999 Mar 12;111(5):181-91. PMID: 10226348
Schwarz HP, Dorner F, Mitterer A, Mundt W, Schlokat U, Pichler L, Turecek PL
Haemophilia 1998;4 Suppl 3:53-62. doi: 10.1046/j.1365-2516.1998.0040s3053.x. PMID: 10028320

Prognosis

Sucker C, Senft B, Scharf RE, Zotz RB
Clin Appl Thromb Hemost 2006 Jul;12(3):305-10. doi: 10.1177/1076029606291428. PMID: 16959683
Elli M, Pinarli FG, Dagdemir A, Dabak N, Fisgin T, Selcuk MB, Sultansuyu S, Acar S
Pediatr Hematol Oncol 2006 Mar;23(2):111-4. doi: 10.1080/08880010500457749. PMID: 16651239

Clinical prediction guides

Sucker C, Senft B, Scharf RE, Zotz RB
Clin Appl Thromb Hemost 2006 Jul;12(3):305-10. doi: 10.1177/1076029606291428. PMID: 16959683

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...